Safety and efficacy of faecal microbiota transplantation in patients with acute uncomplicated diverticulitis: study protocol for a randomised placebo-controlled trial

被引:0
|
作者
Thorndal, Camilla [1 ]
Kragsnaes, Maja Skov [2 ,3 ]
Nilsson, Anna Christine [4 ]
Holm, Dorte Kinggaard [4 ]
Christensen, Rene dePont [5 ]
Ellingsen, Torkell [2 ,3 ]
Kjeldsen, Jens [2 ,6 ]
Bjorsum-Meyer, Thomas [1 ]
机构
[1] Odense Univ Hosp, Dept Surg, Baagoes Alle 15, DK-5000 Odense, Denmark
[2] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[3] Odense Univ Hosp, Dept Rheumatol, Odense, Denmark
[4] Odense Univ Hosp, Dept Clin Immunol, Odense, Denmark
[5] Univ Southern Denmark, Dept Publ Hlth, Res Unit Gen Practice, Copenhagen, Denmark
[6] Odense Univ Hosp, Dept Med Gastrointestinal Dis, Odense, Denmark
关键词
acute uncomplicated diverticulitis; faecal microbiota transplantation; placebo; randomised controlled trial; CLOSTRIDIUM-DIFFICILE INFECTION; GUT MICROBIOTA; MEDICAL-MANAGEMENT; MOLECULAR ANALYSIS; DISEASE; RECURRENT; RISK; HOSPITALIZATION; METAANALYSIS; GUIDELINES;
D O I
10.1177/17562848241309868
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Little is known about the involvement of gut microbiota in the disease course of diverticulitis and the potential benefits of manipulating the gut milieu. We propose to conduct a randomised placebo-controlled feasibility trial of faecal microbiota transplantation (FMT) given as capsules to patients with acute uncomplicated diverticulitis.Objectives: The objective is primarily to investigate the feasibility of clinical safety, explore efficacy associated with FMT in this patient population, and examine changes in patient-reported quality of life and the composition and function of the gut microbiota.Design: Study protocol for a randomised placebo-controlled trial.Methods and analysis: Participants with acute, uncomplicated diverticulitis, as confirmed by computed tomography (CT) scan, will be recruited from Odense University Hospital (Denmark) and randomly assigned to either the intervention group or the control group. The intervention group will consist of 20 patients who receive encapsulated FMT. The control group will also consist of 20 patients, receiving placebo capsules. Primary safety endpoint: Patient safety is monitored by (a) the number of re-admissions and (b) the number of adverse events within 3 months of FMT/placebo; Primary efficacy endpoint: Reduction in the proportion of patients treated with antibiotics within 3 months following FMT/placebo; Secondary outcome: Change from baseline to 3 months in the GI-QLI questionnaire. Results will be analysed using an intention-to-treat approach. Adverse events or unintended consequences will be reported.Ethics and discussion: This is the first study to investigate the safety and efficacy of FMT in patients with acute uncomplicated diverticulitis. The project has the potential to broaden the knowledge and literature on the role of the intestinal microbiota in diverticulitis, and we believe it will elevate our understanding of cause and effect.Trial registration: Informed consent is obtained from all participants. The study is approved by the regional ethics committee (ref. S-20230023) and the Danish Data Protection Agency (ref. 24/2435). The trial was registered on clinicaltrials.gov (NCT06254625) on 10th February 2024.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial
    Haifer, Craig
    Paramsothy, Sudarshan
    Kaakoush, Nadeem O.
    Saikal, Aiasha
    Ghaly, Simon
    Yang, Tao
    Luu, Laurence Don Wai
    Borody, Thomas J.
    Leong, Rupert W.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (02): : 141 - 151
  • [22] Optimising the treatment for uncomplicated acute appendicitis (OPTIMA trial): a protocol for a multicentre, randomised, double-blinded placebo-controlled study
    Wu, Jie
    Jiang, Haiyang
    Li, Shikuan
    Wu, Xiuwen
    Wang, Peige
    Sawyer, Robert
    Ren, Jianan
    BMJ OPEN, 2022, 12 (05):
  • [23] EFFICACY AND SAFETY OF FAECAL MICROBIOTA TRANSPLANTATION FOR ACTIVE PERIPHERAL PSORIATIC ARTHRITIS: A RANDOMISED SHAM-CONTROLLED TRIAL
    Kragsnaes, M. Skov
    Kjeldsen, J.
    Horn, H. C.
    Munk, H. L.
    Pedersen, J. K.
    Just, S. A.
    Ahlquist, P.
    Pedersen, F. Moeller
    De Wit, M.
    Moller, S.
    Andersen, V.
    Kristiansen, K.
    Holt, H. M.
    Holm, D. Kinggaard
    Christensen, R.
    Ellingsen, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 6 - 6
  • [24] Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial
    Hoffmann-Vold, Anna-Maria
    Fretheim, Havard H.
    Sarna, Vikas K.
    Barua, Imon
    Carstens, Maylen N.
    Distler, Oliver
    Khanna, Dinesh
    Volkmann, Elizabeth R.
    Midtvedt, Oyvind
    Didriksen, Henriette
    Dhainaut, Alvilde
    Halse, Anne-Kristine
    Bakland, Gunnstein
    Pesonen, Maiju
    Olsen, Inge
    Molberg, Oyvind
    BMJ OPEN, 2021, 11 (06):
  • [25] Faecal microbiota transplantation for patients with diabetes type 1 and severe gastrointestinal neuropathy (FADIGAS): a randomised, double-blinded, placebo-controlled trial
    Hoyer, Katrine Lundby
    Baunwall, Simon Mark Dahl
    Kornum, Ditte Smed
    Klinge, Mette Winther
    Drewes, Asbjorn Mohr
    Yderstraede, Knud Bonnet
    Thingholm, Louise Bruun
    Mortensen, Martin Steen
    Mikkelsen, Susan
    Erikstrup, Christian
    Hvas, Christian Lodberg
    Krogh, Klaus
    ECLINICALMEDICINE, 2025, 79
  • [26] Efficacy and safety of butylphthalide for patients who had acute ischaemic stroke receiving intravenous thrombolysis or endovascular treatment (BAST trial): study protocol for a randomised placebo-controlled trial
    Zhang, Xuelei
    Wang, Anxin
    Zhang, Jing Yu
    Jia, Baixue
    Huo, Xiaochuan
    Zuo, Yingting
    Tian, Xue
    Wang, Yilong
    Miao, Zhongrong
    BMJ OPEN, 2021, 11 (05):
  • [27] Faecal microbiota transplantation in Ulcerative Colitis: A randomised controlled trial
    Rossen, N.
    Fuentes, S.
    van der Spek, M.
    Tijssen, J.
    Hartman, J.
    Duflou, A.
    Mathus-Vliegen, L.
    de Vos, W.
    Zoetendal, E.
    D'haens, G.
    Ponsioen, C.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S2 - S2
  • [28] Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study
    Halkjaer, Sofie Ingdam
    Christensen, Alice Hojer
    Lo, Bobby Zhao Sheng
    Browne, Patrick Denis
    Guenther, Stig
    Hansen, Lars Hestbjerg
    Petersen, Andreas Munk
    GUT, 2018, 67 (12) : 2107 - 2115
  • [29] Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial
    Baunwall, Simon Mark Dahl
    Andreasen, Sara Ellegaard
    Hansen, Mette Mejlby
    Kelsen, Jens
    Hoyer, Katrine Lundby
    Ragard, Nina
    Eriksen, Lotte Lindgreen
    Stoy, Sidsel
    Rubak, Tone
    Damsgaard, Else Marie Skjode
    Mikkelsen, Susan
    Erikstrup, Christian
    Dahlerup, Jens Frederik
    Hvas, Christian Lodberg
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (12): : 1083 - 1091
  • [30] Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial
    Aroniadis, Olga C.
    Brandt, Lawrence J.
    Oneto, Caterina
    Feuerstadt, Paul
    Sherman, Alex
    Wolkoff, Allan W.
    Kassam, Zain
    Sadovsky, Rotem Gura
    Elliott, Ryan J.
    Budree, Shrish
    Kim, Mimi
    Keller, Marla J.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (09): : 675 - 685